Skip to content
Open access

Safranal, a Natural Neuroprotective Compound, Modulates Plasma Iron Levels, Improves Behavioral Performance, and Demonstrates Dose-Specific Cytoprotection in Alzheimer’s Disease Models

Oct 2026 · International Journal of Molecular Sciences · Vol 27, pp. 9392 · 0 citations · 56 references
Medicine

TL;DR

It is suggested that safranal represents a promising natural candidate for reducing behavioral deficits, supporting peripheral iron status, and offering functional cell survival in AD models.

Abstract

Metal dyshomeostasis contributes to Alzheimer’s disease (AD) by influencing amyloid aggregation, oxidative imbalance, and impaired clearance mechanisms. Safranal, a bioactive constituent of Crocus sativus, exhibits antioxidant properties, but its metal-modulating actions remain insufficiently understood. This study investigated whether safranal modulates metal (Fe, Cu, Zn) levels in an AD rat model while evaluating its cytoprotective rescue capacity against Aβ1-42 induced neurotoxicity in differentiated SH-SY5Y cells. AD was induced in male rats via intracerebroventricular streptozotocin, followed by a four-week safranal administration (0.5 mg/kg/day, ip). Behavioral performance, plasma metal levels (ICP-MS), and cerebral total antioxidant capacity (FRAP) were evaluated alongside histological assessment. Post-treatment protocols were employed to evaluate the effects of safranal on cell viability and apoptosis in differentiated SH-SY5Y cells exposed to Aβ1-42. Longitudinal analyses revealed that safranal attenuated exploratory deficits and recognition memory impairments in AD rats. Decreased plasma iron levels in the AD group were restored by safranal, accompanied by a return of cerebral antioxidant capacity to normal. Although overt hippocampal histological alterations were absent in this early phase, post-treatment with safranal successfully offered a therapeutic rescue window, preserving cell viability and attenuating Aβ1-42-induced apoptotic features in vitro. Safranal demonstrates beneficial neuroprotective effects in AD models by improving behavioral outcomes, partially correcting plasma iron levels, and mediating cytoprotective rescue windows against Aβ1-42-induced cellular toxicity. These findings suggest that safranal represents a promising natural candidate for reducing behavioral deficits, supporting peripheral iron status, and offering functional cell survival in AD models.

Read PDF

Similar papers

Oct 2026

Neuroprotective Effects of Neolamarckia cadamba against β-amyloid-induced Cognitive Dysfunction via Antioxidant and Anti-inflammatory Mechanisms in Rats.

INTRODUCTION Alzheimer's disease is a progressive neurodegenerative disorder characterised by oxidative stress, amyloid-beta accumulation, and neuroinflammation, leading to cognitive decline. Current treatments offer only limited symptomatic relief. This study evaluates the neuroprotective potential of the ethanolic le...

R. Mishra, J. K. Gupta · 0 citations
Open access Oct 2026

Modulation of cholinergic dysfunction, oxidative stress, and neuroinflammation by selected phytochemicals: neuroprotective evidence from in vitro biochemical and cell-based models of Alzheimer’s disease

Alzheimer’s disease is a progressive neurodegenerative disorder associated with cholinergic dysfunction, oxidative stress, neuronal damage, and neuroinflammation. Flavonoids possess multitarget therapeutic potential owing to their antioxidant and anti-inflammatory activities, which contribute to their neuroprotecti...

R. D, Naveen Pathakala · 0 citations
Oct 2026

Isovitexin Attenuates Aβ-Induced Neurotoxicity by Activating SKN-1/Nrf2 Signaling and Suppressing Ferroptosis in Caenorhabditis elegans Models of Alzheimer's Disease.

Results showed that isovitexin significantly extended lifespan, reduced Aβ accumulation, and improved neuromuscular function, demonstrating marked neuroprotective effects, and support further investigation of isovitexin as a candidate for mitigating Aβ-induced neurodegeneration.

Meng-Jiao Hao, Dong-Ni Wu, Ling-Li Sun et al. · 0 citations
Oct 2026

Suppression of ER Stress Underlies Montelukast's Neuroprotective Actions in D-Gal/AlCl3-Induced Alzheimer's Disease in Rats.

Alzheimer's disease (AD) is a neurodegenerative ailment characterized by neuronal and cognitive dysfunctions. Notably, cysteinyl leukotriene receptor 1 (CysLT1R) overexpression was detected in various AD models. It was closely associated with other hallmarks of AD, including increased oxidative stress, neuroinflammatio...

Ahmed H. Mahmoud, Sherehan M. Ibrahim, M. El-Yamany et al. · 0 citations
Open access Sep 2026

Tinosinenside A ameliorates Alzheimer's disease-related pathology in APP/PS1 mice, accompanied by reduced neuroinflammation and altered microglial phenotype-associated marker expression.

Tinospora sinensis (Lour.) Merr. has traditionally been used for its anti-inflammatory properties. Tinosinenside A (Tis A), a major sesquiterpene glycoside isolated from this plant, has shown neuroprotective activity; however, its effects on Alzheimer's disease (AD)-related neuroinflammation remain unclear. This study...

Jing-Jing Wang, Chong Meng, Yong-Yan Xie et al. · 0 citations
Sep 2026

Neurobehavioral and Molecular Rescue by Dapagliflozin in Aluminum Chloride-Induced Alzheimer's Model: Possible Relevance of NF-κB and Aβ(1-42).

Alzheimer's disease (AD), a progressive neurodegenerative disorder, characterized by the deposition of amyloid-β plaques in the hippocampus, leading to cognitive and behavioral impairments. This study investigated the neuroprotective outcome of Dapagliflozin (DAPA), a sodium-glucose cotransporter 2 inhibitor primarily...

Lovekesh Singh, Ghanshyam Das Gupta, Shamsher Singh · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.